Table 1

Demographic and clinical characteristics at start of follow-up in individuals with sarcoidosis and their matched general population comparators

SarcoidosisGeneral population
Individuals857484 192
Age, years49.5 (14.6)49.3 (14.5)
Female3824 (44.6)37 606 (44.7)
Region of residence
 Stockholm1761 (20.5)17 323 (20.6)
 Uppsala-Örebro1897 (22.1)18 620 (22.1)
 West1543 (18.0)15 206 (18.1)
 South1447 (16.9)14 198 (16.9)
 Southeast977 (11.4)9565 (11.4)
 North949 (11.1)9280 (11.0)
Country of birth*
 Nordic7731 (90.2)73 841 (87.7)
 Non-Nordic816 (9.5)10 015 (11.9)
 Missing27 (0.3)336 (0.4)
Education, years
 ≤91732 (20.2)16 974 (20.2)
 10–124202 (49.0)39 216 (46.6)
 ≥132493 (29.1)26 842 (31.9)
 Missing147 (1.7)1160 (1.4)
Married or in registered partnership4153 (48.4)40 366 (47.9)
Calendar period
 2003–20073540 (41.3)34 804 (41.3)
 2008–20135034 (58.7)49 388 (58.7)
Healthcare visits within 2 years before the first sarcoidosis visit, n
 01462 (17.1)43 268 (51.4)
 1–32180 (25.4)21 799 (25.9)
 ≥44932 (57.5)19 125 (22.7)
History of morbidity†
 Hypertension1586 (18.5)12 104 (14.4)
 Diabetes mellitus586 (6.8)3176 (3.8)
 Dyslipidaemia827 (9.6)6218 (7.4)
 Ischaemic heart disease or acute myocardial infarction339 (4.0)2735 (3.2)
 Atrial fibrillation199 (2.3)1361 (1.6)
 Heart valve disease69 (0.8)470 (0.6)
 Chronic obstructive pulmonary disease145 (1.7)681 (0.8)
 Chronic kidney disease115 (1.3)297 (0.4)
 Alcohol-related disorder184 (2.1)2134 (2.5)
 Autoimmune disease629 (7.3)3428 (4.1)
  • Data are n, n (%), or mean (SD). Category percentages may not sum up to 100 owing to rounding.

  • *Nordic countries include Sweden, Denmark, Norway, Finland and Iceland.

  • †Evaluated in the period up to 3 months before the first sarcoidosis visit in the National Patient Register or the corresponding date for matched general population comparators.